Data on the survival effects of supportive care compared to second-line multimodal treatment for glioblastoma progression are scarce. Thus, the authors assessed survival in two population-based, similar cohorts from two European university hospitals with different treatment strategies at first progression.
The authors retrospectively identified patients with newly diagnosed glioblastoma treated at two neurooncological centers. After diagnosis, patients from both centers received identical treatments, but at tumor progression each center used a different approach. In the majority of cases, at center A (Greece), supportive care or a single therapeutic modality was offered at progression, whereas center B (Germany) provided multimodal second-line therapy. The main outcome measure was survival after progression (SaP). The influence of the treatment strategy on SaP was assessed by multivariate analysis.
One hundred three patients from center A and 156 from center B were included. Tumor progression was observed in 86 patients (center A) and 136 patients (center B). At center A, 53 patients (72.6%) received supportive care alone, while at center B, 91 patients (80.5%) received second-line treatment. Progression-free survival at both centers was similar (9.4 months [center A] vs 9.0 months [center B]; p = 0.97), but SaP was significantly improved in the patients treated with multimodal second-line therapy at center B (7 months, 95% CI 5.3–8.7 months) compared to those treated with supportive care or a single therapeutic modality at center A (4.5 months, 95% CI 3.5–5.5 months; p = 0.003). In the multivariate analysis, the treatment center was an independent prognostic factor for overall survival (HR 1.59, 95% CI 0.17–2.15; p = 0.002).
Treatment strategy favoring multimodal second-line treatment over minimal treatment or supportive care at glioblastoma progression is associated with significantly better overall survival.
ABBREVIATIONSEORTC = European Organisation for Research and Treatment of Cancer; GBM = glioblastoma; KPS = Karnofsky Performance Scale; MGMT = O6-methylguanine-DNA methyltransferase; OS = overall survival; PFS = progression-free survival; QOL = quality of life; SaP = survival after progression.
Delgado-FernandezJGarcia-PalleroMABlascoGPenanesJRGil-SimoesRPulidoP: Usefulness of reintervention in recurrent glioblastoma: an indispensable weapon for increasing survival. World Neurosurg108:610–6172017
DieboldGDucrayFHenaineAMFrappazDGuyotatJCartalat-CarelS: Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. J Clin Pharm Ther39:642–6482014
FietkauRPutzFLahmerGSemrauSBusleiR: Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution. Strahlenther Onkol189:993–9952013
McNamaraMGLwinZJiangHTempletonAJZadehGBernsteinM: Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neurooncol117:147–1522014
NavaFTramacereIFittipaldoABruzzoneMGDimecoFFariselliL: Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997–2010. Neuro Oncol16:719–7272014
RyuSBuattiJMMorrisAKalkanisSNRykenTCOlsonJJ: The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol118:489–4992014
SignorovitchJLiNOhashiEDastaniHShawJOrsiniL: Overall survival (OS), quality of life (QOL), and neurocognitive function (NF) in recurrent glioblastoma multiforme (GBM): a systematic literature review. Value Health18:A4332015(Abstract)
StuppRHegiMEMasonWPvan den BentMJTaphoornMJJanzerRC: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol10:459–4662009
StuppRTaillibertSKannerAAKesariSSteinbergDMTomsSA: Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA314:2535–25432015
SuchorskaBWellerMTabatabaiGSenftCHauPSabelMC: Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. Neuro Oncol18:549–5562016
TaalWOosterkampHMWalenkampAMDubbinkHJBeerepootLVHanseMC: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol15:943–9532014
WellerMvan den BentMTonnJCStuppRPreusserMCohen-Jonathan-MoyalE: European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol18:e315–e3292017